| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 39.26 | 40.65 | 1.85 | 22.75 |
Op profit growth | 72.97 | 5.85 | 5.45 | -0.29 |
EBIT growth | 144.08 | 20.4 | 9.41 | 13.14 |
Net profit growth | 189.12 | 13.47 | 25.2 | 84.65 |
Profitability ratios (%) | ||||
OPM | 9.97 | 8.03 | 10.67 | 10.3 |
EBIT margin | 8.44 | 4.81 | 5.62 | 5.23 |
Net profit margin | 8.17 | 3.93 | 4.87 | 3.96 |
RoCE | 23.37 | 10.58 | 9.42 | 8.52 |
RoNW | 6.84 | 3.29 | 3.5 | 2.37 |
RoA | 5.65 | 2.16 | 2.04 | 1.61 |
Per share ratios (₹) | ||||
EPS | 2.16 | 0.75 | 0.66 | 0.53 |
Dividend per share | 0 | 0 | 0 | 0 |
Cash EPS | 1.48 | -0.07 | -0.1 | -0.22 |
Book value per share | 9.44 | 6.31 | 5.02 | 4.36 |
Valuation ratios | ||||
P/E | 14.88 | 12.72 | 46.74 | 35.84 |
P/CEPS | 21.64 | -128.98 | -293.32 | -83.21 |
P/B | 3.4 | 1.51 | 6.14 | 4.35 |
EV/EBIDTA | 10.68 | 6.71 | 22.14 | 15.6 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 0 |
Tax payout | -1.44 | -14.13 | 0 | 0 |
Liquidity ratios | ||||
Debtor days | 49.1 | 55.52 | 64.63 | 55.43 |
Inventory days | 48.2 | 46.07 | 42.59 | 32.73 |
Creditor days | -65.03 | -80.75 | -102.43 | -85.05 |
Leverage ratios | ||||
Interest coverage | -56.08 | -20.7 | -7.83 | -4.12 |
Net debt / equity | -0.11 | 0.33 | 0.56 | 0.82 |
Net debt / op. profit | -0.42 | 1.37 | 1.98 | 2.62 |
Cost breakup (₹) | ||||
Material costs | -65.69 | -65.34 | -60.76 | -61.43 |
Employee costs | -11.41 | -12.88 | -12.61 | -11.7 |
Other costs | -12.91 | -13.74 | -15.93 | -16.54 |
With this approval, Morepen Laboratories aims to strengthen its presence in China, which is one of the world’s largest pharmaceutical markets.
Developed from scratch, this drug offers an inexpensive and superior alternative to current treatments, making it accessible to hundreds of millions of patients.
Here are some of the stocks that may see significant price movement today: Tata Motors, ITC, Kalyan Jewellers, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
